Psoriatic arthritis: a review
Psoriatic arthritis (PsA) is an immunologically triggered, chronic inflammatory arthropathy, which can have a lasting influence on the quality of life of affected individuals. An early diagnosis is essential in order to institute adequate therapy. Both dermatologists and rheumatologists should be in...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
22 April 2010
|
| In: |
Journal der Deutschen Dermatologischen Gesellschaft
Year: 2010, Volume: 8, Issue: 5, Pages: 332-339 |
| ISSN: | 1610-0387 |
| DOI: | 10.1111/j.1610-0387.2009.07334.x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1610-0387.2009.07334.x Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1610-0387.2009.07334.x 
|
| Author Notes: | Anne Amherd-Hoekstra, Helmut Näher, Hanns-Martin Lorenz, Alexander H. Enk |
| Summary: | Psoriatic arthritis (PsA) is an immunologically triggered, chronic inflammatory arthropathy, which can have a lasting influence on the quality of life of affected individuals. An early diagnosis is essential in order to institute adequate therapy. Both dermatologists and rheumatologists should be involved in the diagnosis and management of the disorder. Mild forms can be managed with NSAID and systemic corticosteroids. In acute forms with a confirmed diagnosis and oligo- to polyarticular involvement, disease-modifying therapy with DMARD (Disease-Modifying Antirheumatic Drugs) is indicated. New studies of PsA show that tumor necrosis factor (TNF) plays a central role in mediating inflammation. For this reason, TNF-α antagonists have become more and more important as a second-line therapy for PsA. |
|---|---|
| Item Description: | Gesehen am 22.11.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1610-0387 |
| DOI: | 10.1111/j.1610-0387.2009.07334.x |